BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IM-1021 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IM-1021\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06823167-10970@assetmemo.bio
DTSTAMP:20261121T005710Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:IM-1021: Phase 1 readout est. (NCT06823167)
DESCRIPTION:IM-1021\, phase 1.\nStudy: A Phase 1 Study of IM-1021 in Partic
 ipants With Advanced Cancer\nEstimated primary completion: May 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/im-1021#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06823167
URL:https://assetmemo.bio/drug/im-1021#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
